With Higher Specificity, Alzinova’s Vaccine Candidate Offers a New Approach to Tackle Alzheimer’s DiseaseDate: 2022-01-05
The European Medicines Agency (EMA) recently recommended the refusal of the marketing authorisation for Aduhelm, a medicine intended for the treatment of Alzheimer’s disease.
“At the same time, the Swedish research company Alzinova is working to offer a better, more specific and effective treatment alternative” – Read more in the BioStock-article below.
Link to BioStock Article (in Swedish)
For more information in English, see Our Progams-web page.